Actavis’ Investment Venture To Acquire Stake In Techpool Bio-Pharma
This article was originally published in PharmAsia News
Executive Summary
Investor firm Smart Nice, majority-owned by pharmaceutical company Actavis, will accept 20 million shares of Techpool Bio-Pharma from Guangzhou Bopu and buy another 20 million shares at 5 yuan per share. Shanghai Industrial Pharmaceutical Investment and its subsidiary Huarui Investments will decrease their equity in Techpool from 51 percent to 40.8 percent, while Smart Nice will become a strategic investor with 40 percent stake. According to sources, both companies have signed an MOU to collaborate in the areas of medical science, technology, business operation and pharmaceutical-related fields. (Click here for more - Chinese language)
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.